TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07742384: An Open-label, Fixed Sequence Study to Evaluate the Effect of Famotidine on the Pharmacokinetics and Safety of Taletrectinib in Healthy Adult Participant

Sponsor: Nuvation Bio Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 56 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07742384 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07742384 Rescue Dossier →